Biomarin Pharmaceutical Inc Stock Research

Market Summary

USD97.24+1.95

Market Closed

2.05%

BMRN Alerts

1 major insider sales recently.
Big jump in Earnings (Y/Y)
Losses in recent quarter

BMRN Stock Price

BMRN RSI Chart

BMRN Valuation

Market Cap

18.1B

Price/Earnings (Trailing)

127.94

Price/Sales (Trailing)

8.64

EV/EBITDA

64.99

Price/Free Cashflow

329.63

BMRN Price/Sales (Trailing)

BMRN Profitability

Operating Margin

76.92%

EBT Margin

7.14%

Return on Equity

3.08%

Return on Assets

2.22%

Free Cashflow Yield

0.3%

BMRN Fundamentals

BMRN Revenue

Revenue (TTM)

2.1B

Revenue Y/Y

19.5%

Revenue Q/Q

6.37%

BMRN Earnings

Earnings (TTM)

141.6M

Earnings Y/Y

99.57%

Earnings Q/Q

96.26%

Price Action

52 Week Range

70.73117.77

(Low)(High)

Last 7 days

5.8%

Last 30 days

-4.3%

Last 90 days

-7.9%

Trailing 12 Months

22.3%

BMRN Financial Health

Current Ratio

4.67

BMRN Investor Care

Shares Dilution (1Y)

1.27%

Diluted EPS (TTM)

0.75

Peers (Alternatives to Biomarin Pharmaceutical)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	129.1B	26.3B	4.25%	2.73%	19.7	4.9	1.32%	11.18%
GILD	103.5B	27.3B	2.11%	42.30%	22.53	3.79	-0.09%	-26.23%
MRNA	59.1B	19.3B	6.22%	-15.71%	7.07	3.07	4.29%	-31.47%
BIIB	40.1B	10.2B	1.95%	30.37%	13.18	3.95	-7.36%	95.80%
MID-CAP
NBIX	9.6B	1.5B	-3.77%	7.31%	61.97	6.43	31.34%	72.43%
DNLI	3.0B	108.5M	-19.30%	-32.38%	-9.14	27.47	122.90%	-12.19%
BBIO	2.5B	107.9M	50.18%	65.38%	-5.15	23.14	54.84%	17.36%
BEAM	2.2B	60.9M	-25.07%	-49.29%	-7.55	35.83	17.51%	22.00%
SMALL-CAP
RCUS	1.3B	112.0M	-4.12%	-47.72%	-4.77	11.36	-70.76%	-603.77%
REPL	989.9M	7.0M	-20.18%	2.82%	-6.31	141.2	131.81%	-45.39%
NVAX	596.3M	2.0B	-28.83%	-91.18%	-0.91	0.3	72.89%	62.27%
FATE	515.7M	96.3M	-13.40%	-86.70%	-1.83	5.35	72.44%	-32.79%
SGMO	283.5M	111.3M	-44.26%	-71.33%	-1.47	2.55	0.54%	-7.86%
VXRT	101.5M	107.0K	-2.91%	-84.84%	-0.94	949.05	-88.00%	-52.91%
IBIO	25.7M	-	64.06%	-80.69%	-0.32	3.21	0.51%	-185.61%

Financials for Biomarin Pharmaceutical

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	4.4%	2,096	2,008	1,912	1,880	1,846
Cost Of Revenue	1.6%	484	476	463	467	471
S&GA Expenses	3.4%	854	826	792	780	759
R&D Expenses	1.8%	650	638	638	641	629
Costs and Expenses	2.4%	1,946	1,900	1,854	1,850	1,929
EBITDA	42.1%	268	188	146	127	-
EBITDA Margin	36.1%	0.13*	0.09*	0.08*	0.07*	-
Earnings Before Taxes	48.7%	150	101	56.00	36.00	-75.35
EBT Margin	42.5%	0.07*	0.05*	0.03*	0.02*	-
Interest Expenses	-1.4%	16.00	16.00	15.00	15.00	15.00
Net Income	68.7%	142	84.00	54.00	39.00	-64.08
Net Income Margin	61.6%	0.07*	0.04*	0.03*	0.02*	-
Free Cahsflow	-17.1%	55.00	66.00	16.00	47.00	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	1.8%	6,375	6,264	6,146	6,063	6,005
Current Assets	2.6%	2,751	2,683	2,518	2,394	2,274
Cash Equivalents	-4.9%	725	762	620	605	587
Inventory	6.5%	894	839	802	786	777
Net PPE	2.0%	1,073	1,052	1,049	1,040	1,035
Goodwill	0%	196	196	196	196	196
Liabilities	4.5%	1,772	1,696	1,641	1,671	1,739
Current Liabilities	13.0%	589	521	465	490	546
Shareholder's Equity	0.8%	4,603	4,569	4,500	4,391	4,266
Retained Earnings	0.0%	-789	-788	-777	-804	-930
Additional Paid-In Capital	1.3%	5,405	5,336	5,273	5,206	5,192
Accumulated Depreciation	2.7%	782	762	741	721	-
Shares Outstanding	0.2%	186	186	185	185	184

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-2.4%	176	180	119	146	305
Share Based Compensation	1.5%	196	193	188	196	197
Cashflow From Investing	3.4%	-20.03	-20.74	-117	-207	-366
Cashflow From Financing	-23.3%	-18.65	-15.12	-23.69	-0.96	-0.05
Buy Backs	NaN%	0.00	0.00	-	-	-

Risks for BMRN

What is the probability of a big loss on BMRN?

64.6%

Probability that Biomarin Pharmaceutical stock will be more than 20% underwater in next one year

30%

Probability that Biomarin Pharmaceutical stock will be more than 30% underwater in next one year.

18.5%

Probability that Biomarin Pharmaceutical stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BMRN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Biomarin Pharmaceutical was unfortunately bought at previous high price.

Drawdowns

Returns for BMRN

Cumulative Returns on BMRN

4.5%

10-Year Cumulative Returns

2.1%

7-Year Cumulative Returns

3.3%

5-Year Cumulative Returns

4.9%

3-Year Cumulative Returns

What are the long-term rolling returns for BMRN?

FIve years rolling returns for Biomarin Pharmaceutical.

Annualized Returns

Which funds bought or sold BMRN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-27	Neo Ivy Capital Management	sold off	-100	-68,000	-	-%
2023-03-23	MetLife Investment Management, LLC	added	0.47	72,924	394,711	-%
2023-03-17	American Portfolios Advisors	reduced	-21.96	-9,058	35,858	-%
2023-03-15	B. Riley Wealth Advisors, Inc.	new	-	271,351	271,351	0.01%
2023-03-10	BAILLIE GIFFORD & CO	unchanged	-	1,486	8,486	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	added	2.7	15,822,600	78,168,600	0.09%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-48.3	-31,873,000	54,541,000	0.27%
2023-03-02	OLIVER LAGORE VANVALIN INVESTMENT GROUP	unchanged	-	1,175	5,175	-%
2023-02-28	Voya Investment Management LLC	added	5.08	1,750,370	7,937,370	0.01%
2023-02-24	National Pension Service	reduced	-4.35	3,893,290	27,661,000	0.05%

Latest Funds Activity

Are funds buying BMRN calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BMRN

No. of Funds

Biomarin Pharmaceutical News

Schedule 13G FIlings of Biomarin Pharmaceutical

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	dodge & cox	7.7%	14,383,663	SC 13G/A
Feb 13, 2023	capital research global investors	3.0%	5,651,001	SC 13G/A
Feb 09, 2023	primecap management co/ca/	9.46%	17,580,859	SC 13G/A
Feb 09, 2023	vanguard group inc	9.34%	17,365,080	SC 13G/A
Feb 03, 2023	blackrock inc.	8.2%	15,206,690	SC 13G/A
Mar 11, 2022	blackrock inc.	7.6%	14,021,292	SC 13G/A
Feb 14, 2022	dodge & cox	8.1%	14,825,049	SC 13G/A
Feb 10, 2022	primecap management co/ca/	9.7%	17,804,780	SC 13G/A
Feb 09, 2022	vanguard group inc	8.91%	16,351,031	SC 13G/A
Feb 08, 2022	blackrock inc.	7.6%	14,021,292	SC 13G

BMRN Fair Value

Biomarin Pharmaceutical fair value in different scenarios

The table shows the Fair Value estimates for Biomarin Pharmaceutical for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	23.66 -75.67%	28.40 -70.79%	38.90 -60.00%	49.62 -48.97%	60.19 -38.10%
Current Inflation	22.20 -77.17%	26.25 -73.00%	35.14 -63.86%	44.14 -54.61%	53.00 -45.50%
Very High Inflation	20.39 -79.03%	23.65 -75.68%	30.70 -68.43%	37.76 -61.17%	44.70 -54.03%

Historical Biomarin Pharmaceutical Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Biomarin Pharmaceutical

View All Filings

Date Filed	Form Type	Document
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 14, 2023	4	Insider Trading
Mar 13, 2023	144	Notice of Insider Sale Intent
Mar 10, 2023	144	Notice of Insider Sale Intent

Latest Insider Trading transactions for BMRN

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-16	Mueller Brian	sold (taxes)	-371,118	93.41	-3,973	evp, chief financial officer
2023-03-16	Davis George Eric	sold (taxes)	-1,864,180	93.41	-19,957	evp, chief legal officer
2023-03-16	Ajer Jeffrey Robert	sold (taxes)	-1,915,840	93.41	-20,510	evp, chief commercial officer
2023-03-16	BIENAIME JEAN JACQUES	sold (taxes)	-8,278,270	93.41	-88,623	chief executive officer
2023-03-16	FUCHS HENRY J	sold (taxes)	-3,362,760	93.41	-36,000	president, worldwide r&d
2023-03-15	BIENAIME JEAN JACQUES	acquired	-	-	36,100	chief executive officer
2023-03-15	Davis George Eric	acquired	-	-	8,900	evp, chief legal officer
2023-03-15	Burkhart Erin	acquired	-	-	3,760	gvp, chief accounting officer
2023-03-15	FUCHS HENRY J	sold (taxes)	-421,064	87.74	-4,799	president, worldwide r&d
2023-03-15	Ajer Jeffrey Robert	acquired	-	-	10,110	evp, chief commercial officer

About Biomarin Pharmaceutical

Jean-Jacques BienaimÃƒÂ©

www.biomarin.com

3040

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Income Statement

2022-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

^[1]

REVENUES:

Total revenues

$ 2,096,039

$ 1,846,275

$ 1,860,455

OPERATING EXPENSES:

Cost of sales

483,669

470,515

524,272

Research and development

649,606

628,793

628,116

Selling, general and administrative

854,009

759,375

737,669

Intangible asset amortization and contingent consideration

67,193

69,933

66,658

Gain on sale of nonfinancial assets, net

(108,000)

(52,820)

Total operating expenses

1,946,477

1,928,616

1,903,895

INCOME (LOSS) FROM OPERATIONS

149,562

(82,341)

(43,440)

Interest income

18,034

10,482

16,610

Interest expense

(15,970)

(15,337)

(29,309)

Other income (expense), net

(2,050)

11,846

7,142

INCOME (LOSS) BEFORE INCOME TAXES

149,576

(75,350)

(48,997)

Provision for (benefit from) income taxes

8,015

(11,270)

(903,026)

NET INCOME (LOSS)

$ 141,561

$ (64,080)

$ 854,029

^[2],[3]

EARNINGS (LOSS) PER SHARE, BASIC (in dollars per share)

$ 0.76

$ (0.35)

$ 4.72

EARNINGS (LOSS) PER SHARE, DILUTED (in dollars per share)

$ 0.75

$ (0.35)

$ 4.50

Weighted-average common shares outstanding, basic (in shares)

185,266

182,852

180,804

Weighted average common shares outstanding, diluted (in shares)

188,963

182,852

191,678

Net product revenues

REVENUES:

Total revenues

$ 2,042,025

$ 1,783,498

$ 1,805,861

Royalty and other revenues

REVENUES:

Total revenues

$ 54,014

$ 62,777

$ 54,594

[1]	Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.
[2]	Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.
[3]	December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.

BMRN Balance Sheet

2022-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

^[1]

Current assets:

Cash and cash equivalents

$ 724,531

$ 587,276

Short-term investments

567,006

426,599

Accounts receivable, net

461,316

373,399

Inventory

894,083

776,669

Other current assets

104,521

110,442

Total current assets

2,751,457

2,274,385

Noncurrent assets:

Long-term investments

333,835

507,793

Property, plant and equipment, net

1,073,366

1,035,461

Intangible assets, net

338,569

388,652

Goodwill

196,199

Deferred tax assets

1,505,412

1,450,161

Other assets

176,236

152,121

Total assets

6,375,074

6,004,772

Current liabilities:

Accounts payable and accrued liabilities

572,959

498,265

Short-term contingent consideration

15,925

48,232

Total current liabilities

588,884

546,497

Noncurrent liabilities:

Long-term convertible debt, net

1,083,019

1,079,077

Long-term contingent consideration

15,167

Other long-term liabilities

100,015

98,362

Total liabilities

1,771,918

1,739,103

Stockholders’ equity:

Common stock, $0.001 par value: 500,000,000 shares authorized; 186,250,719 and 183,912,514 shares issued and outstanding, respectively

186

184

Additional paid-in capital

5,404,895

5,191,502

Company common stock held by the Nonqualified Deferred Compensation Plan

(8,859)

(9,689)

Accumulated other comprehensive income (loss)

(3,867)

14,432

Accumulated deficit

(789,199)

(930,760)

Total stockholders’ equity

4,603,156

4,265,669

Total liabilities and stockholders’ equity

$ 6,375,074

$ 6,004,772

[1]	Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.